ORCL
THC
BAX
DGX

RUSCKOWSKI STEPHEN H

Known title: DirectorCIK: 0001142624

RUSCKOWSKI STEPHEN H's purchase track record

RUSCKOWSKI STEPHEN H has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
9/29/2026ORCL$3.48Mpendingpending

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

Oracle: No Recent Company News. Oracle has not had any new company‑specific announcements in the past week. The recent news items listed relate to other technology firms and do not directly affect Oracle’s operations or outlook. Investors can continue to rely on existing fundamentals and market data for guidance.

this person other insiders at ORCL

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets. Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.

this person other insiders at THC

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 4, 2026

Baxter International publishes inaugural Connected Hospital Report. Baxter International released its first Connected Hospital Report, highlighting its role in remote cardiac monitoring and digital health infrastructure. The company is also featured in recent discussions regarding potential warning signs in Wall Street favorites and overlooked investment angles. These developments provide context for the stock's current position within its 52-week range.

this person other insiders at BAX

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.

this person other insiders at DGX

Transaction History

ORCL▲ Buy$3.5M
THC▲ Buy—
BAX▲ Buy$0
BAX▲ Buy$0
BAX▲ Buy$0
THC▲ Buy$0
DGX▲ Buy$12.2M
DGX▼ Sell$5.7M
DGX▼ Sell$492K
DGX▲ Buy$0
DGX▼ Sell$861K
DGX▲ Buy$1.0M
DGX▼ Sell$959K
DGX▼ Sell$363K
DGX▼ Sell$93K
DGX▲ Buy$1.3M
DGX▼ Sell$584K
DGX▼ Sell$128K
DGX▼ Sell$1.4M
DGX▲ Buy$13.1M
DGX▼ Sell$17.7M
DGX▲ Buy$13.5M
DGX▼ Sell$21.9M
DGX▲ Buy$3.6M
DGX▼ Sell$4.7M
DGX▼ Sell$113K
DGX▼ Sell$28K
DGX▲ Buy$3.7M
DGX▼ Sell$5.8M
DGX▼ Sell$142K
DGX▼ Sell$43K
DGX▲ Buy$9.1M
DGX▼ Sell$4.2M
DGX▲ Buy$0
DGX▼ Sell$971K
DGX▼ Sell$294K

We use analytics to understand how market-wall is used. No personal data is sold.